News About: Pharm. Industry
Majority of Koreans take nutrients
55.6 percent of Koreans take vitamins or iron supplements for better health on regular basis, according to a survey.
The finding came from a telephone survey of 541 people aged over 19 on September 5 by the Realmet...
KGC to transfer varicella vaccine technology to Vietnam
Local drug maker Korea Green Cross Corporation plans to transfer its developed production technology of varicella vaccine to a Vietnamese company until 2011.
KGC and Vietnam's VABIOTEC signed a memorandum of unders...
Placenta market draws spotlight
The domestic placenta market is emerging as this miracle ingredient - the embryonic tissue formed in pregnant mammals and used for decades as a wrinkle reducer - is one beautifier that has long been kept under wraps.
...
Yungjin ties with Kaneka on coenzyme Q10Yungjin Pharm said on September 6 that it has joined with Japanese chemical and resin maker Kaneka Corp. to import the latter's coenzyme Q10 that is becoming increasingly popula...
|
Dong-A unveils new medication for periodonal diseaseDong-A Pharm said it has launched Depasa for the prevention and treatment of gum disease.
Depasa is available as capsules containing lysozyme HCl, tocopherol acetate and asco...
|
First prescription omega-3 product offers proven benefitKuhnil Pharm's Omacor, an omega-3-acid ethyl esters product approved by the Korea Food and Drug Administration in May 2006, has captured a sizable market volume with an expected...
|
Novartis, Pfizer to co-market Exforge in October
Novartis Korea and Pfizer Korea said on September 6 that they will begin the co-marketing of Exforge, a combined formulation of amlodipine, a dihydropyridine calcium-channel blocker, and valsartan, an angiotensin II r...
GSK presents clinical trial results at 12th World Conference on Lung Cancer
GlaxoSmithKline presented results from their clinical results of new medicines at the 12th World Conference on Lung Cancer being held in Seoul, Korea September 2-6, 2007.
The data presented at this symposium by wor...
Iressa is comparable to docetaxel in survival rate
AstraZeneca Korea said on September 5 that patients with non-small cell lung cancer (NSCLC) treated with the oral anti-cancer drug Iressa (gefitinib) in the INTEREST study had equivalent (non-inferior) survival to tho...
TDS PALM acquires NES certification for hydrogel wound dressing technology
TDS PALM, a local biopharmaceutical company, said that it has won a New Excellent Technology (NES) certification for locally invented hydrogel wound dressing.
The hydrogel dressing made with TDS's new technology is...
